Targeting mutated proteins by small molecules such as IDH1/2 or FLT3 inhibitors has considerably broadened the therapeutic repertoire in AML and improved survival (reviewed in refs. Kindler et al, 2010; Chaturvedi et al, 2013). The gene discussed is FLT3; the disease is acute myeloid leukemia.